HK1138772A1 - Methods for using vasopressin antagonists with anthracycline chemotherapy agents to reduce cardiotoxicity and/or improve survival - Google Patents

Methods for using vasopressin antagonists with anthracycline chemotherapy agents to reduce cardiotoxicity and/or improve survival

Info

Publication number
HK1138772A1
HK1138772A1 HK10105468.0A HK10105468A HK1138772A1 HK 1138772 A1 HK1138772 A1 HK 1138772A1 HK 10105468 A HK10105468 A HK 10105468A HK 1138772 A1 HK1138772 A1 HK 1138772A1
Authority
HK
Hong Kong
Prior art keywords
methods
chemotherapy agents
improve survival
vasopressin antagonists
anthracycline
Prior art date
Application number
HK10105468.0A
Other languages
English (en)
Inventor
Yongge Liu
Junichi Kambayashi
Original Assignee
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd
Publication of HK1138772A1 publication Critical patent/HK1138772A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Hospice & Palliative Care (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK10105468.0A 2007-05-15 2010-06-02 Methods for using vasopressin antagonists with anthracycline chemotherapy agents to reduce cardiotoxicity and/or improve survival HK1138772A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US93808907P 2007-05-15 2007-05-15
PCT/US2008/063374 WO2008144269A2 (en) 2007-05-15 2008-05-12 Methods for using vasopressin antagonists with anthracycline chemotherapy agents to reduce cardiotoxicity and/or improve survival

Publications (1)

Publication Number Publication Date
HK1138772A1 true HK1138772A1 (en) 2010-09-03

Family

ID=40122254

Family Applications (2)

Application Number Title Priority Date Filing Date
HK10105468.0A HK1138772A1 (en) 2007-05-15 2010-06-02 Methods for using vasopressin antagonists with anthracycline chemotherapy agents to reduce cardiotoxicity and/or improve survival
HK13103539.7A HK1176318A1 (en) 2007-05-15 2013-03-21 Injection device

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK13103539.7A HK1176318A1 (en) 2007-05-15 2013-03-21 Injection device

Country Status (25)

Country Link
US (1) US8372830B2 (zh)
EP (1) EP2146721B1 (zh)
KR (1) KR101508797B1 (zh)
CN (2) CN103550233A (zh)
AR (1) AR066544A1 (zh)
AU (1) AU2008254273B2 (zh)
BR (1) BRPI0811134A2 (zh)
CA (1) CA2685186A1 (zh)
CO (1) CO6280574A2 (zh)
CY (1) CY1114163T1 (zh)
DK (1) DK2146721T3 (zh)
ES (1) ES2421639T3 (zh)
HK (2) HK1138772A1 (zh)
HR (1) HRP20130920T1 (zh)
IL (1) IL202094A (zh)
MX (1) MX2009012164A (zh)
MY (1) MY150682A (zh)
NZ (1) NZ581126A (zh)
PL (1) PL2146721T3 (zh)
PT (1) PT2146721E (zh)
RU (1) RU2470643C2 (zh)
SI (1) SI2146721T1 (zh)
TW (1) TWI428131B (zh)
UA (1) UA99914C2 (zh)
WO (1) WO2008144269A2 (zh)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2211906A2 (en) * 2007-11-07 2010-08-04 Janssen Pharmaceutica, N.V. Combination therapy comprising angiotensin converting enzyme inhibitors and vasopressin receptor antagonists
WO2013176955A1 (en) * 2012-05-21 2013-11-28 The General Hospital Corporation Cardioprotective compounds, their use with chemotherapy, and methods for identifying them
US20150238502A1 (en) * 2012-10-18 2015-08-27 University Of South Florida Compositions and Methods for Treating Stroke
EP2970311A4 (en) 2013-03-14 2016-11-23 Brigham & Womens Hospital BMP INHIBITORS AND METHODS OF USE
US11491154B2 (en) 2013-04-08 2022-11-08 Dennis M. Brown Therapeutic benefit of suboptimally administered chemical compounds
US10172911B2 (en) 2013-10-01 2019-01-08 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of modulating erythropoiesis with arginine vasopressin receptor 1B molecules
WO2016011019A1 (en) 2014-07-15 2016-01-21 The Brigham And Women's Hospital, Inc. Compositions and methods for inhibiting bmp
CN116063580A (zh) 2016-01-04 2023-05-05 艾得佩索拉公司 肽类似物
WO2017139154A1 (en) * 2016-02-09 2017-08-17 Adepthera Llc Dosing and use of long-acting clr/ramp agonists
WO2018226875A2 (en) * 2017-06-07 2018-12-13 University Of Kansas Methods and medicaments for the treatment of renal cell carcinoma
US20190153059A1 (en) 2017-06-30 2019-05-23 Adepthera Llc Peptide analogs
TWI737974B (zh) 2018-04-09 2021-09-01 美商標徑製藥公司 用於治療增生性失調的劑量方案

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US574455A (en) * 1897-01-05 Switch-lock
US5744455A (en) * 1988-01-27 1998-04-28 New York University Reduction of anthracycline-induced cardiotoxicity
TWI322689B (en) * 2003-02-24 2010-04-01 Otsuka Pharma Co Ltd Method for treating severe heart failure and medicament therefor

Also Published As

Publication number Publication date
HK1176318A1 (en) 2013-07-26
CA2685186A1 (en) 2008-11-27
US8372830B2 (en) 2013-02-12
TW200916104A (en) 2009-04-16
ES2421639T3 (es) 2013-09-04
KR101508797B1 (ko) 2015-04-06
SI2146721T1 (sl) 2013-10-30
KR20100019439A (ko) 2010-02-18
CO6280574A2 (es) 2011-05-20
EP2146721A4 (en) 2010-08-25
NZ581126A (en) 2012-04-27
BRPI0811134A2 (pt) 2014-09-30
RU2009146376A (ru) 2011-06-20
AU2008254273B2 (en) 2013-03-28
CN101808517A (zh) 2010-08-18
MX2009012164A (es) 2009-12-09
CN103550233A (zh) 2014-02-05
AU2008254273A1 (en) 2008-11-27
WO2008144269A2 (en) 2008-11-27
EP2146721A2 (en) 2010-01-27
IL202094A0 (en) 2010-06-16
AR066544A1 (es) 2009-08-26
UA99914C2 (ru) 2012-10-25
CY1114163T1 (el) 2016-08-31
RU2470643C2 (ru) 2012-12-27
TWI428131B (zh) 2014-03-01
DK2146721T3 (da) 2013-07-22
WO2008144269A3 (en) 2010-01-21
US20100249104A1 (en) 2010-09-30
MY150682A (en) 2014-02-28
PL2146721T3 (pl) 2013-12-31
HRP20130920T1 (hr) 2013-11-08
IL202094A (en) 2015-06-30
EP2146721B1 (en) 2013-07-10
PT2146721E (pt) 2013-07-18

Similar Documents

Publication Publication Date Title
HK1138772A1 (en) Methods for using vasopressin antagonists with anthracycline chemotherapy agents to reduce cardiotoxicity and/or improve survival
CR20220281A (es) Derivados de pirazolilo útiles como agentes anti-cancerígenos
PH12015502628B1 (en) Pyrazolopyrrolidine derivatives and their use in the treatment of disease
DOP2005000039A (es) Hidrocloruro de [4-(5-aminometil-2-fluoro-fenil)- piperidin-1-il]-(4-bomo-3-metil-5-propoxi-tiofen-2-il)-metanona como un inhibidor de la triptasa de mastocitos
PT2038290E (pt) Moduladores de receptor do tipo toll 7
NZ700881A (en) Compositions and methods comprising celecoxib or related compounds and dextromethorphan
UA93709C2 (ru) 12-имидазолил-1-додеканол и его применение b изготовлении фармацевтических композиций
TW200726765A (en) Triazolopyridine cannabinoid receptor 1 antagonists
MX356032B (es) Compuestos indola y métodos para tratar el dolor visceral.
MX2014002171A (es) Tratamientos de combinacion para hepatitis c.
MX2010005632A (es) Analogos de aminoglucosidos antibacterianos.
WO2005112633A3 (en) Compounds and compositions for delivering active agents
MX2011013201A (es) Composiciones para tratar adiccion a drogas y para mejorar comportamiento relacionado a la adiccion.
MX2010003923A (es) Formulacion farmaceutica de valsartan.
WO2011159100A3 (ko) 항암 활성을 나타내는 약제학적 조성물
MX2009005798A (es) Recuperacion de apoplejia.
MX2007010886A (es) Metodos y formulaciones de acarbosa para tratar constipacion cronica.
UY30847A1 (es) Uso de derivados de mononitrato de dianhidrohexita como agentes para el tratamiento de trastornos intestinales
AR061233A1 (es) Formulacion de liberacion prolongada de naltrexona
WO2009019693A3 (en) Analgesic effect of jasmonate derivatives
MX2010005009A (es) Uso de compuestos inmunomoduladores para el tratamiento de trastornos asociados con disfunciones endoteliales.
MX2008002272A (es) Compuestos de ciclopropilo y composiciones para suministrar agentes activos.
WO2009137436A3 (en) Peptide conjugates
TNSN08093A1 (en) Quinoline derivatives and use as antitumor agents
WO2011094208A3 (en) Methods and pharmaceutical compositions for preventing and treating renal impairment

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20170512